GLOW Blend: Dosage, Benefits & Side Effects
Also known as: GHK-Cu + BPC-157 + TB-500 blend
By Peptide Assistant Editorial Team · · · 15 sources cited
Overview
GLOW Blend is a three-peptide vial that combines GHK-Cu, BPC-157 and TB-500. It is sold for skin rejuvenation and tissue repair. Each ingredient has its own research record, mostly in cells and animals, and none has controlled human evidence as an injection. The blend itself has not been studied: no clinical or animal study has tested these three peptides together. The amount of each peptide per vial varies by vendor, so check the label.
Mechanism of Action
GLOW Blend combines three peptides that have been studied separately. GHK-Cu is a copper-binding tripeptide found in human plasma. It stimulated collagen synthesis in fibroblast cultures and increased collagen, protein and glycosaminoglycans in rat wound chambers. BPC-157 is a 15-amino-acid peptide derived from a protein in gastric juice. In rat and cell studies it promoted tendon fibroblast outgrowth and migration and new blood vessel formation through VEGFR2 signaling. TB-500 is a synthetic, acetylated fragment (amino acids 17–23, LKKTETQ) of thymosin beta-4. This actin-binding region promoted endothelial cell migration and vessel sprouting in cell studies and dermal wound repair in aged mice; most other research was done with full-length thymosin beta-4, not the fragment. The rationale for blending is that these actions (collagen production, blood vessel growth and cell migration) are all part of tissue repair and might add up. That has not been tested for the three together. The one controlled study of BPC-157 combined with TB-500, in rat Achilles tendon repair (2026), found no added benefit over either peptide alone.
GLOW Blend Benefits: What the Research Shows
- GHK-Cu: human evidence is topical only. In a randomized, placebo-controlled trial, GHK-Cu gel increased closure of diabetic plantar ulcers (98.5% versus 60.8% median area closure), while a randomized trial of a tripeptide-copper cream in 86 venous ulcer patients found no difference from placebo. No human study of injected GHK-Cu was found
- BPC-157: a 2025 systematic review found 36 studies, 35 of them preclinical; in animals it improved tendon, ligament, muscle and bone healing. Human evidence is three small uncontrolled studies with 30 participants in total
- TB-500: a synthetic peptide with the same seven-amino-acid sequence promoted dermal wound repair in aged mice about as well as full-length thymosin beta-4. All human trials used full-length thymosin beta-4, not TB-500
- The combination: no study has tested GHK-Cu, BPC-157 and TB-500 together. The one controlled study of BPC-157 combined with TB-500, in rat Achilles tendon repair (2026), found no added benefit over either peptide alone
GLOW Blend Dosage
- Vial contents: GHK-Cu, BPC-157 and TB-500 (70 mg total is a common size). The split between the three varies by vendor, and the dose of each peptide depends on that split
- Typical dose: per vendor instructions, usually 0.5–1 mL subcutaneous injection daily or every other day
- Common cycle: 4–8 weeks on, 2–4 weeks off
- Inject subcutaneously in the abdominal area for systemic distribution
- Some protocols include direct facial/scalp injections for targeted effects (under practitioner guidance)
- Best used as part of a broader skin-health protocol including sun protection and adequate hydration
- Evening dosing may optimize synergy with nighttime repair processes
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
GLOW Blend Side Effects & Safety
Known Side Effects
- Side effects of the blend have not been studied in humans; the effects below come from user reports of the individual peptides
- Injection site reactions: redness, mild stinging, occasional bruising
- Mild skin flushing after injection, reported with GHK-Cu
- Temporary fatigue, lightheadedness or mild nausea, reported with TB-500 and BPC-157
- Headache reported occasionally during first week
- Rare: allergic reaction to specific blend components — discontinue if rash develops
- Theoretical concern: BPC-157 and TB-500 both promote new blood vessel growth in laboratory studies, which could in theory support an existing tumor; this has not been studied in people
Safety Profile
The blend has not been safety-tested, and none of its three ingredients has adequate human safety data as an injection. The FDA lists injectable GHK-Cu, BPC-157 and the TB-500 fragment among bulk drug substances that may present significant safety risks in compounding. It cites possible immunogenicity for GHK-Cu and BPC-157, and says it has identified no human exposure data for the TB-500 fragment. BPC-157's human record is three small uncontrolled studies. BPC-157 and TB-500 are prohibited in sport at all times under the WADA Prohibited List. People with active cancer should avoid the blend as a precaution, because BPC-157 and TB-500 promote blood vessel growth in laboratory studies. Those with Wilson's disease or copper sensitivity should avoid it because of the GHK-Cu. Avoid during pregnancy and breastfeeding. Blends add a further unknown: the amount of each peptide per vial varies by vendor, so ask for a certificate of analysis (COA) that lists each ingredient. No drug interaction studies have been done.
What to Expect
This timeline comes from user reports; the blend has not been studied in humans. Week 1–2: Skin may feel slightly different in texture — smoother, more hydrated. Some users experience a brief purging phase. Mild glow or radiance may be noticeable. Weeks 3–4: Visible improvements in skin tone, texture, and firmness. Fine lines appear softer. Skin hydration improves. Weeks 5–8: Significant improvements in overall complexion. Skin appears more youthful with better elasticity and fewer visible imperfections. Results continue to build after discontinuation as collagen remodeling continues for several weeks.
Common Stacks
Storage & Handling
Follow vendor-specific storage instructions. Generally: store lyophilized at 2–8°C; reconstituted at 2–8°C, use within 3–4 weeks. Protect from light. Blends may have shorter post-reconstitution stability than single-peptide products due to potential interactions between components.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026.
- The Prohibited List. World Anti-Doping Agency. 2026.
- Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026.
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025.
- Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026.
- Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011.
- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017.
- Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012.
- Philp D, Badamchian M, Scheremeta B, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003.
- Philp D, Huff T, Gho YS, et al. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003.
- Tham A, Hodgkins CW, Kennedy JG. Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. J Am Acad Orthop Surg. 2026.
- Mulder GD, Patt LM, Sanders L, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994.
- Bishop JB, Phillips LG, Mustoe TA, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992.
- Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993.
- Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988.
Related Peptides
Track GLOW Blend in Your Protocol
Log your GLOW Blend doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free